Introducing Azathioprine prepared according to the Imuran standard—a well‑established immunosuppressive agent that inhibits purine synthesis to prevent organ rejection. This formulation modulates lymphocyte proliferation to improve graft survival and overall transplant outcomes. Experience improved transplant results, reduced rejection risk, and enhanced immune balance with this targeted tablet therapy.